Erythropoietin receptors on cancer cells: Exciting perspectives, difficult to appreciate [3]

Blood

Volumn 108, Issue 3, 2006, Pages 1107-1108

  Henke, Michael ^a   Verma, Ajay ^b   Acs, Geza ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CHAPERONE; CYTOKINE RECEPTOR; ERYTHROPOIETIN ANTIBODY; ERYTHROPOIETIN RECEPTOR; HEAT SHOCK PROTEIN 70; MESSENGER RNA; RECOMBINANT ERYTHROPOIETIN; TRYPSIN;

ANEMIA; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; CANCER CELL; CELL CULTURE; DRUG EFFECT; GENE CONSTRUCT; GENETIC CODE; HEMATOPOIETIC TISSUE; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LIGAND BINDING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEDICAL INFORMATION; MOLECULAR WEIGHT; PLASMID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; STARVATION; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

EID: 33746590683     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-03-006742     Document Type: Letter

References (13)

1. Elliott S, Busse L, Bass MB, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood. 2006;107:1892-1895.
2. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 2001;61:3561-3565.
3. Arcasoy MO, Amin K, Chou SC, Haroon ZA, Varia M, Raleigh JA. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res. 2005;11:20-27.
4. Dagnon K, Pacary E, Commo F, et al. Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res. 2005;11:993-999.
5. Hoogsteen IJ, Peeters WJ, Marres HA, et al. Erythropoietin receptor is not a surrogate marker for tumor hypoxia and does not correlate with survival in head and neck squamous cell carcinomas. Radiother Oncol. 2005;76:213-218.
6. Winter SC, Corbridge RJ, Cox GJ, Harris AL. Hypoxia and anaemia in head and neck squamous cell carcinoma: mechanisms of therapy failure and provision of new therapeutic targets. Clin Otolaryngol. 2005;30:99-104.
7. Siren AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98:4044-4049.
8. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A. 2000;97:10526-10531.
9. Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate. 2006;66:135-145.
10. Lai SY, Childs EE, Xi S, et al. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene. 2005;24:4442-4449.
11. Um M, Lodish HF. Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways. J Biol Chem. 2006;281:5648-5656.
12. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23:5960-5972.
13. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260.